Skip to main content

Table 1 Characteristics of 40 esophageal squamous cell carcinoma patients with malignant fistulae

From: Concurrent chemoradiotherapy combined with enteral nutrition support: a radical treatment strategy for esophageal squamous cell carcinoma patients with malignant fistulae

Characteristic No. of patients (%) 1-year OS rated (%) P value
Sex    0.006
 Men 37 (92.5) 67.6  
 Women 3 (7.5) 0.0  
Agea (years) 58 (41–80)   
ECOG performance status    0.267
 0–1 11 (27.5) 68.2  
 2 29 (72.5) 55.2  
Primary tumor location    0.403
 Upper 12 (30.0) 50.0  
 Middle 26 (65.0) 65.4  
 Lower 2 (5.0) 100.0  
T category of primary tumorb    0.392
 T1 2 (5.0) 100.0  
 T2 3 (7.5) 100.0  
 T3 21 (52.5) 57.1  
 T4 14 (35.0) 57.1  
Clinical stage of primary tumorb    0.526
 IIA–IIB 2 (5.0) 100  
 IIIA–IIIC 29 (72.5) 62.1  
 IV 9 (22.5) 55.5  
NRS score of 3–4c
 Before nutrition support 22 (55.0) e  
 After nutrition support 6 (15.0)  
Hemoglobin level after CCRTa (g/L) 110 (56–156)  
Total energy intakea (kcal/day) 2166 (1956–2213)  
Total protein intakea (g/kg per day) 1.53 (1.41–1.76)  
Fistula closure 32 (80.0)  
Time to fistula closurea (weeks) 5 (2–11)  
Fistula site    0.435
 Trachea and bronchus 7 (17.5) 57.1  
 Mediastinum 33 (82.5) 63.6  
Radiation dosea (Gy) 60 (46–68)   <0.001
 <60 14 (35.0) 50.0  
 ≥60 26 (65.0) 69.2  
Concurrent chemotherapy    0.333
 DDP + 5-FU 7 (17.5) 42.9  
 Docetaxel-based regimens 33 (82.5) 66.7  
Clinical tumor response after CCRT    <0.001
 CR 12 (30.0) 91.7  
 PR 20 (50.0) 65.0  
 SD 3 (7.5) 33.3  
 PD 5 (12.5) 0  
  1. ECOG, Eastern Cooperative Oncology Group; NRS, nutrition risk screening; CCRT, concurrent chemoradiotherapy; DDP, cisplatin; 5-FU, 5-fluorouracil; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease
  2. aThese values are presented as median followed by range in parentheses. Other values are presented as the number of patients with the percentage in parentheses
  3. bBased on the American Joint Committee on Cancer tumor, node, and metastasis (TNM) classification (7th edition)
  4. cThe patients with NRS score of 1–2 are not listed in this table
  5. dOnly the values that were compared between subgroups are listed and analyzed
  6. eThe data were not applicable